当前位置: 首页 >> 检索结果
661. In subclinical AF, the benefit of apixaban vs. aspirin on stroke or systemic embolism trended higher with CHA2DS2-VASc >4.
Lopes RD, Granger CB, Wojdyla DM, et al. Apixaban vs aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA. J Am Coll Cardiol. 2024;84:354-364. 39019530.
662. In adults with BMI ≥27 kg/m2 and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA1c level.
Lingvay I, Deanfield J, Kahn SE, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT. Diabetes Care. 2024;47:1360-1369. 38907684.
663. In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.
Usman MS, Bhatt DL, Hameed I, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024;12:447-461. 38768620.
665. A New Horizon: The Promise of the National Institutes of Health's Landmark Designation of Persons With Disabilities as a Population With Health Disparities.666. Risk for Financial Precarity From Hospitalization: Implications for Targeting Financial Assistance in Medicare.
作者: Paula Chatterjee.;Eliza Macneal.;Syama R Patel.;Eric T Roberts.
来源: Ann Intern Med. 2024年177卷12期1601-1609页
High out-of-pocket costs in Medicare may leave many beneficiaries in financial precarity. Beneficiaries with modest incomes are often ineligible for Medicaid (which covers most out-of-pocket Medicare costs) and may have insufficient resources to pay an unexpected health care bill. This has prompted calls to improve financial protections, but the target population remains uncharacterized.
670. Projected Impact and Cost-Effectiveness of Novel Molecular Blood-Based or Stool-Based Screening Tests for Colorectal Cancer.
作者: Uri Ladabaum.;Ajitha Mannalithara.;Robert E Schoen.;Jason A Dominitz.;David Lieberman.
来源: Ann Intern Med. 2024年177卷12期1610-1620页
Cell-free DNA blood tests (cf-bDNA) and next-generation stool tests could change colorectal cancer (CRC) screening.
671. Comparative Effectiveness and Safety of Atorvastatin Versus Rosuvastatin : A Multi-database Cohort Study.
作者: Shiyu Zhou.;Ruixuan Chen.;Jiao Liu.;Zhixin Guo.;Licong Su.;Yanqin Li.;Xiaodong Zhang.;Fan Luo.;Qi Gao.;Yuxin Lin.;Mingzhen Pang.;Lisha Cao.;Xin Xu.;Sheng Nie.
来源: Ann Intern Med. 2024年177卷12期1641-1651页
Rosuvastatin and atorvastatin are the most widely prescribed moderate- to high-intensity statins. However, evidence on their efficacy and safety during actual use is limited.
672. 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache.
作者: Jason J Sico.;Natasha M Antonovich.;Jennifer Ballard-Hernandez.;Andrew C Buelt.;Amy S Grinberg.;Franz J Macedo.;Ian W Pace.;James Reston.;James Sall.;Friedhelm Sandbrink.;Karen M Skop.;Thomas R Stark.;Rebecca Vogsland.;Lisa Wayman.;Aven W Ford.
来源: Ann Intern Med. 2024年177卷12期1675-1694页
Headache medicine and therapeutics evidence have been rapidly expanding and evolving since the 2020 U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) clinical practice guideline (CPG) for the management of headache. Therefore, the CPG was revised in 2023, earlier than the standard 5-year cycle. This article reviews the 2023 CPG recommendations relevant to primary care clinicians for treatment and prevention of migraine and tension-type headache (TTH).
677. Cardiovascular Disease Mortality Among Native Hawaiian and Pacific Islander Adults Aged 35 Years or Older, 2018 to 2022.
作者: Rebecca C Woodruff.;Joseph Keawe'aimoku Kaholokula.;Lorinda Riley.;Xin Tong.;LaTonia C Richardson.;Kotryna Diktonaite.;Fleetwood Loustalot.;Adam S Vaughan.;Omoye E Imoisili.;Donald K Hayes.
来源: Ann Intern Med. 2024年177卷11期1509-1517页
Native Hawaiian and Pacific Islander (NHPI) adults have historically been grouped with Asian adults in U.S. mortality surveillance. Starting in 2018, the 1997 race and ethnicity standards from the U.S. Office of Management and Budget were adopted by all states on death certificates, enabling national-level estimates of cardiovascular disease (CVD) mortality for NHPI adults independent of Asian adults.
678. Qualitative Analysis of Patients' and Physicians' Attitudes and Behaviors Toward Billing Patient Portal Messages.
作者: Jordan M Alpert.;Elizabeth Pfoh.;Victoria Criswell.;Maria C Tang.;Elizabeth E Stanley.;Sandra Hong.;Robert Saper.;Eric Yudelevich Blumrosen.;Michael B Rothberg.
来源: Ann Intern Med. 2024年177卷12期1734-1736页 679. Opportunities for Innovation in Smoking Cessation Therapies: A Perspective From the National Institutes of Health and U.S. Food and Drug Administration.
作者: Haider J Warraich.;Brian A King.;Wilson M Compton.;Evan S Herrmann.;Mary Thanh Hai.;Robert M Califf.;Monica M Bertagnolli.
来源: Ann Intern Med. 2025年178卷1期122-125页 680. Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial.
作者: Kathleen V Fitch.;Markella V Zanni.;Jennifer Manne-Goehler.;Marissa R Diggs.;Arijeet K Gattu.;Judith S Currier.;Gerald S Bloomfield.;Chiu-Bin Hsiao.;Samir K Gupta.;Judith A Aberg.;Carlos D Malvestutto.;Carl J Fichtenbaum.;Michael T Lu.;Pamela S Douglas.;Heather J Ribaudo.;Steven K Grinspoon.
来源: Ann Intern Med. 2024年177卷11期1449-1461页
REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) led to new guidelines for statin use among people with HIV (PWH) with low to moderate risk for atherosclerotic cardiovascular disease (ASCVD). Little is known about the natural history of diabetes mellitus (DM) or mechanisms contributing to statin effects on DM among this population.
|